Skip to Main Content

Mumps IgG Antibodies

Principle

Mumps virus, a member of the Paramyxoviridae family, causes an acute, self-limited systemic illness, most commonly in children aged 5–19 years. The hallmark is parotid gland swelling, often accompanied by fever, headache, and fatigue.

A significant increase in Mumps-reactive IgG by EIA is observed in over 90% of paired acute (4–5 days after symptom onset) and convalescent (2–3 weeks after onset) sera. Mumps IgM antibodies may also be detected.

Assay mechanism: Diluted patient serum is incubated with purified native Mumps antigen bound to microwells. If IgG antibodies are present, they form antigen-antibody complexes. Conjugate binds to these complexes. Unbound conjugate is washed away, substrate is added, and in the presence of bound enzyme, a measurable end product forms. Absorbance at 450 nm (reference 600–630 nm) is proportional to Mumps IgG concentration.

Specimen Requirements

Specimen

Serum (red-top tube with no additive or serum separator tube, SST)

Collection

Separate serum from clot as soon as possible to prevent hemolysis.

Processing

Separate serum from clot as soon as possible to prevent hemolysis.

Storage and Transport

Store/transport at 15–30°C for ≤8 hours; 2–8°C for ≤48 hours; freeze at ≤ –20°C if delayed. Avoid repeated freeze–thaw cycles.

Unacceptable Specimens

Hemolyzed or unseparated specimens.

Method

ELISA

Normal Range

Index Value and Interpretation

  • < 0.90 - No detectable Mumps IgG antibody; result does not exclude Mumps infection. Retest within 4&ndash;6 weeks if early infection is suspected.
  • 0.90-1.09 - Equivocal for IgG antibodies to Mumps. Sample should be retested. If retest results are equivocal, the sample should be reported as equivocal, tested by another method, or a new sample should be tested
  • > 1.10 - Mumps IgG antibody detected; indicative of current or past infection

Turnaround Time

One Week

References

  • King GE, Markowitz LE, Heath J, Redd SC, Coleman S, Bellini WJ, Sievert A. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. 1996;275(9):704–707.
  • Williams WW, Sosis DM, Kaplan KM, Hersh BS, Preblud SR. Vaccine-preventable diseases on college campuses: the emergence of mumps. J Am Coll Health. 1989;37(5):197–203.

Back to Reproductive Immunology